AngioDynamics (NASDAQ:ANGO) Announces Quarterly Earnings Results

AngioDynamics (NASDAQ:ANGO) announced its quarterly earnings results on Thursday. The medical instruments supplier reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.13, FiscalAI reports. The business had revenue of $78.42 million during the quarter, compared to analysts’ expectations of $76.77 million. AngioDynamics had a negative net margin of 9.02% and a negative return on equity of 2.28%.

Here are the key takeaways from AngioDynamics’ conference call:

• AngioDynamics reported Q3 revenue of $78.4M, up 8.9% YoY with MedTech up 19%, and raised FY26 net sales guidance to $313.5–$315.5M and adjusted EBITDA to $10–$12M (third consecutive upward revision).
• Auryon delivered its nineteenth consecutive quarter of double‑digit growth as increased hospital adoption and product line extensions (radial access, 1.7 mm catheters) drive volume and improved pricing dynamics.
• The combined mechanical thrombectomy portfolio (AlphaVac + AngioVac) grew ~18% YoY, with AlphaVac +47% YoY and +24% sequential, and the company has enrolled first patients in the pivotal APEX‑Return trial targeting approval in Q1 2027.
• NanoKnife revenue rose 21% (capital +24.9%, probes +20%), supported by the Jan 1 implementation of a CPT Category I code and expanded European indications that should boost capital placements and probe utilization.
• Gross margin fell 110 bps to 52.9% due to tariffs, inflation, and a manufacturing transition; tariffs were $1.3M in Q3 and are expected to be $4–$6M for FY26, and a planned $3–$5M inventory build for sterilization shutdowns could make FY26 cash flow slightly negative despite expected strong Q4 cash generation.

AngioDynamics Price Performance

Shares of NASDAQ ANGO traded down $0.29 during midday trading on Thursday, hitting $11.65. The company’s stock had a trading volume of 382,041 shares, compared to its average volume of 552,603. The firm has a market capitalization of $480.34 million, a price-to-earnings ratio of -17.39 and a beta of 0.43. The business’s fifty day simple moving average is $10.86 and its two-hundred day simple moving average is $11.55. AngioDynamics has a 1 year low of $8.36 and a 1 year high of $13.99.

Institutional Investors Weigh In On AngioDynamics

Hedge funds have recently added to or reduced their stakes in the business. Kemnay Advisory Services Inc. purchased a new position in AngioDynamics in the 4th quarter valued at approximately $27,000. State of Wyoming acquired a new stake in shares of AngioDynamics in the second quarter valued at $31,000. Russell Investments Group Ltd. raised its stake in shares of AngioDynamics by 329.5% in the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock valued at $47,000 after acquiring an additional 3,213 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in AngioDynamics by 359.0% in the second quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock valued at $54,000 after purchasing an additional 4,268 shares during the period. Finally, BNP Paribas Financial Markets grew its stake in AngioDynamics by 106.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,473 shares of the medical instruments supplier’s stock worth $83,000 after purchasing an additional 3,846 shares in the last quarter. 89.43% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ANGO. Zacks Research cut shares of AngioDynamics from a “strong-buy” rating to a “hold” rating in a research report on Monday. Wall Street Zen cut AngioDynamics from a “buy” rating to a “hold” rating in a research note on Sunday, December 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Wednesday, January 21st. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, AngioDynamics currently has a consensus rating of “Hold” and an average price target of $19.33.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.